PositiveID announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office covering an interface that employs radio frequency communication for checking glucose levels.
The provisional patent covers the use of radio frequency technology to help sense and communicate changes in glucose levels in the blood through an electromechanical drive-based wireless molecular sensor to an external reader.
In conjunction with partner Receptors, LLC., PositiveID is now in Phase II development of its implantable glucose-sensing microchip, which is expected to be completed in mid-2010.
Phase II is to optimize the sensing system for its glucose response in the presence of blood and interstitial fluid matrix components and demonstrate the integration of the components into a stable and reproducible glucose sensor.
The implantable glucose-sensing microchip will consist of a radio frequency-powered molecular sensor that uses a combination of the analyte binding surface chemistry with micro electro mechanical system technology and radio frequency inductive powered sensing.